Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Devgen nv (Euronext Brussels: DEVG), an agro-biotech company that shapes the field of hybrid rice in India and Southeast Asia and innovates in crop protection technologies, today issued a business update and its three-month financial results ending 31 March 2012. read more
Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from vzw VIB. read more
"The ease at which Thrombogenics recently raised € 78m has put Belgian biotech at the European top at the start of 2012", Jan De Kerpel, KBC Securities read more
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has received a transparency declaration from OppenheimerFunds Inc. in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market. read more
In accordance with Article 15 §1 of the Act of 2 May 2007 on the disclosure of major shareholdings, Devgen nv today announces the issuance of 11,479 common shares by the Company as the result of the exercise of warrants. As a result of this transaction, Devgen now has 24,277,879 shares outstanding. read more
Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises. read more
